Lung cancer, as a malignant tumor with both high incidence and mortality in China, is one of
the major causes of death in our population and one of the major public health problems in …

Advances in monotherapy and combination therapy of S-1 for patients with advanced non-small
cell lung cancer: a narrative review - PMC Back to Top Skip to main content NIH NLM Logo …

Objectives Given the modest efficacy of docetaxel in advanced non-small cell lung cancer
(NSCLC), this study assesses the therapeutic potential and safety profile of anlotinib in …

Interventions: After chemotherapy alone failed, the patient received 6 courses of anlotinib
combined with chemotherapy. The tumor had significantly reduced in size and the recurrent …

Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with
advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study …

For patients with locally unresectable recurrent nasopharyngeal carcinoma who relapsed
after 2 years of radiotherapy, re-radiotherapy is also the preferred treatment. However, for …

Background For patients who have contradictions or failed to checkpoint inhibitors,
chemotherapy is still the standard second line option to treat non-oncogene addicted …

Introduction: At the time of diagnosis, most patients with lung cancer are in an inoperable
stage, with distant metastases. Most often, these patients have metastases to the brain …